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Abstract
The NPHS2	gene,	encoding	the	slit	diaphragm	protein	podocin,	accounts	for	genetic	
and	 sporadic	 forms	 of	 nephrotic	 syndrome	 (NS).	 Patients	 with	 NS	 often	 present	
symptoms	of	volume	retention,	such	as	oedema	formation	or	hypertension.	The	pri‐
mary	dysregulation	 in	 sodium	handling	 involves	an	 inappropriate	activation	of	 the	
epithelial	sodium	channel,	ENaC.	Plasma	proteases	in	a	proteinuria‐dependent	fash‐
ion	 have	 been	made	 responsible;	 however,	 referring	 to	 the	 timeline	 of	 symptoms	
occurring	 and	 underlying	mechanisms,	 contradictory	 results	 have	 been	 published.	
Characterizing	the	mouse	model	of	podocyte	inactivation	of	NPHS2	(Nphs2∆pod)	with	
respect	to	volume	handling	and	proteinuria	revealed	that	sodium	retention,	hyper‐
tension	and	gross	proteinuria	appeared	sequentially	in	a	chronological	order.	Detailed	
analysis	of	Nphs2∆pod	during	early	sodium	retention,	revealed	increased	expression	
of	full‐length	ENaC	subunits	and	αENaC	cleavage	product	with	concomitant	increase	
in	ENaC	activity	as	tested	by	amiloride	application,	and	augmented	collecting	duct	
Na+/K+‐ATPase	 expression.	Urinary	 proteolytic	 activity	was	 increased	 and	 several	
proteases	were	 identified	by	mass	spectrometry	 including	cathepsin	B,	which	was	
found	to	process	αENaC.	Renal	expression	levels	of	precursor	and	active	cathepsin	B	
were	increased	and	could	be	localized	to	glomeruli	and	intercalated	cells.	Inhibition	
of	cathepsin	B	prevented	hypertension.	With	the	appearance	of	gross	proteinuria,	
plasmin	 occurs	 in	 the	 urine	 and	 additional	 cleavage	 of	 γENaC	 is	 encountered.	 In	
conclusion,	characterizing	the	volume	handling	of	Nphs2∆pod	revealed	early	sodium	
retention	occurring	independent	to	aberrantly	filtered	plasma	proteases.	As	an	un‐
derlying	mechanism	cathepsin	B	 induced	αENaC	processing	 leading	 to	augmented	
channel	activity	and	hypertension	was	identified.
K E Y W O R D S
epithelial	sodium	channel,	focal	segmental	glomerulosclerosis,	hypertension,	nephrotic	
syndrome
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1  | INTRODUC TION
The NPHS2	gene,	encoding	the	slit	diaphragm	protein	podocin,	ac‐
counts	for	43%	of	familial	and	10%	of	sporadic	forms	of	nephrotic	
syndrome	(NS).1,2	Conditional	inactivation	of	podocin	in	adult	mice	is	
a	novel	model	system	for	NS	resulting	from	focal	segmental	glomer‐
ulosclerosis	(FSGS),3	which	recapitulates	human	disease	formation.
In	the	NS,	the	underlying	dysregulation	 in	volume	homeostasis	
was	 shown	 to	 be	 an	 intrarenal	 defect4	 located	 beyond	 the	 distal	
convolutions	 in	 the	 renal	 connecting	 tubule	 and	 collecting	 ducts.	
Abnormal	high	activity	of	the	epithelial	sodium	channel	(ENaC)	was	
proven	to	be	the	reason	for	the	increased	transepithelial	sodium	re‐
absorption.5	ENaC	plays	a	key	 role	 in	 regulating	extracellular	 fluid	
homeostasis	and	blood	pressure.	Numerous	studies	of	animal	mod‐
els	with	proteinuria	and	sodium	retention	demonstrated	 increased	
full‐length	subunit	expression	of	ENaC	and	proteolytical	processing	
of	 the	 ENaC	 subunits	 alpha	 and	 gamma.6‐9	 In	 animal	models	with	
NS,	 the	 increased	 expression	 level	 of	 ENaC	was	 demonstrated	 to	
be	 independent	 of	 its	 hormonal	 stimulation.	 Various	 attempts	 in	
blocking	hormones	known	to	activate	ENaC	did	not	abolish	volume	
retention.7,10	Augmented	ENaC	activity	also	results	from	proteolytic	
processing	of	the	large	extracellular	domain	of	α‐	and	γENaC.	A	dual	
cleavage	 event	 in	 either	 subunit	 releases	 small	 intrinsic	 inhibitory	
tracts	transitioning	channels	to	a	more	active	state.11	While	furin,	an	
endogenous	protease,	was	shown	to	cleave	αENaC	twice,	it	cleaves	
the	γENaC	only	once.	Additional	proteases,	 including	extracellular	
proteases,	are	needed	for	 the	second	 incision	 in	γENaC	to	release	
the	inhibitory	tract.	Several	proteases	processing	γENaC	were	iden‐
tified12,13	including	plasmin	in	the	development	of	NS.14,15
Regarding	 the	 timeline	 of	 the	 appearance	 of	 sodium	 retention	
and	proteinuria,	 contradictory	 results	 have	been	published.	 In	 the	
rat	model	of	PAN‐induced	nephrosis,	sodium	retention	was	shown	
to	start	before	or	at	 the	same	time	as	 the	onset	of	proteinuria.7,16 
Consequently,	the	question	arises	whether	glomerular	plasmin	leak‐
age	is	the	only	mechanism	for	ENaC‐induced	sodium	retention.	Both,	
the	 rat	model	of	PAN‐induced	nephrosis	 and	 the	mouse	model	of	
doxorubicin‐induced	 NS17	 develop	 volume	 retention	 and	 oedema	
very	fast	within	a	couple	of	days,	additionally	both	models	show	a	
high	number	of	non‐responders	and	animal	drop‐out	during	the	ex‐
periment	rendering	timeline	analysis	difficult.	The	inducible	mouse	
model	of	podocyte	inactivation	of	NPHS2	was	presented	earlier	to	
develop	 NS	 with	 albuminuria,	 hypercholesteremia	 and	 hyperten‐
sion	with	progressive	podocin	loss	and	at	4	weeks	after	induction	of	
NPHS2	deletion,	an	FSGS	is	fully	established.3	Thus,	the	aim	of	the	
study	was	to	characterize	this	inducible	mouse	model	of	podocyte	
inactivation	of	NPHS2	with	respect	to	volume	handling	and	protein‐
uria,	to	carefully	examine	the	timeline	of	the	symptom	appearance	
and	 to	 identify	 new	mechanism	 for	 the	dysregulated	 sodium	han‐
dling	during	the	development	of	NS.
We	 used	 Nphs2fl/fl(control)	 and	 Nphs2fl/flcrossbred with induc‐
ible	 podocyte‐specific	 Cre recombinase	 transgenic	 mice,	 termed	
Nphs2∆pod	 hereafter	 and	 found	 that	 sodium	 retention	 and	 hy‐
pertension	 established	 before	 the	 onset	 of	 an	 unselective	 gross	
proteinuria.	Increased	ENaC	channel	activity,	proteolytic	processing	
of	αENaC	 together	with	 the	 appearance	of	 proteases	 in	 the	urine	
were	encountered.	Among	several	lysosomal	enzymes	identified	by	
proteomic	analysis,	only	cathepsin	B	was	able	to	cleave	αENaC	and	
augment	channel	 activity.	 Inhibition	of	 cathepsin	B	 influenced	 the	
development	 of	 hypertension	 demonstrating	 its	 important	 role	 in	
this	disease	model.
2  | METHODS
Detailed	methods	are	presented	in	the	supplement	files.
2.1 | Animals and treatments
All	animal	experiments	were	conducted	according	to	the	NIH	Guide	
for	 the	 care	 and	 use	 of	 Laboratory	 animals,	 as	well	 as	 the	 Swiss	
and	 German	 law	 for	 the	 welfare	 of	 animals	 and	 were	 approved	
by	 local	 authorities	 (2013_06E_FR,	 23614;	 2016_28_FR,	 28328;	
V242‐20597/2018).	Mice	were	housed	in	a	SPF	facility	with	free	ac‐
cess	to	chow	and	tap	water	and	a	12‐hour	day/night	cycle.	Breeding	
and	 genotyping	 was	 performed	 as	 described.3 Nphs2fl/fl(control)	
and	 Nphs2fl/flcrossbred with	 inducible	 podocyte‐specific	 Cre re‐
combinase	transgenic	mice,	termed	Nphs2∆pod,3	were	used.	For	the	
induction	 of	 knockout	 leading	 to	 focal	 segmental	 glomeruloscle‐
rosis,	6	weeks	old	Nphs2∆pod	and	control	mice	received	tamoxifen	
(33	mg/kg	per	d	for	5	d;	Sigma,	Buchs,	Schweiz)	by	daily	ip	injection	
for	4	days	in	the	evening	after	spot	urine	sampling	and	blood	pres‐
sure	measurements.	A	second	set	of	animal	experiments	was	per‐
formed	(V242‐20597/2018)	using	amiloride	(Sigma‐Aldrich)	10	µg/g	
body	weight	administered	i.p.	once	daily	starting	on	the	first	day	of	
the	experiment,	simultaneously	with	the	tamoxifen	injection,	till	the	
end	of	the	experiment	at	14	days.	A	third	set	of	animal	experiments	
(2016_28_FR,	28328)	was	conducted	using	the	cathepsin	B	inhibi‐
tor	 CA‐074Me	 (MerckMillipore,	 Darmstadt,	 Germany).	 Six	 weeks	
old	Nphs2∆pod	and	control	received	Me‐074	or	vehicle	by	osmotic	
mini	pump	 (1002,	Alzet,	USA)	 for	14	days.	 Implantation	of	pumps	
was	performed	1	day	after	the	first	tamoxifen	injection.	CA‐074Me	
was	administered	by	mini‐pump	infusion	at	a	rate	of	2.5	mL/h	(1	mg/
mL	in	saline	with	1.5%	DMSO,	representing	a	dose	of	0.15	mg/kg/
day).	Vehicle	control	 infusion	was	conducted	with	1.5%	DMSO	 in	
saline.	All	mice	entered	also	completed	the	experiment.
2.2 | Presentation of data and statistical analysis
Quantitative	data	are	presented	as	means	±	SEM.	Statistical	compar‐
isons	were	performed	with	the	GraphPad	Prism	Software	Package	
6	 (GraphPad	Software	 Inc,	La	 Jolla,	CA,	USA).	For	 statistical	 com‐
parison,	the	non‐parametric	Mann–Whitney	U	test,	the	parametric	
two‐tailed	Student’s	t	test	and,	where	appropriate	one‐way	ANOVA	
followed	 by	 Tukey,	 Dunnett	 or	 Newman‐Keuls	 post	 hoc	 test	 was	
employed.	P	 values	of	 less	 than	0.05	were	considered	 statistically	
significant.
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3  | RESULTS
3.1 | Podocin loss leads to nephrotic syndrome
Inactivation	of	podocin	 resulted	 in	 transiently	 reduced	urinary	so‐
dium/creatinine	ratio,	which	was	significantly	reduced	between	day	
4	 to	7	 after	 tamoxifen	 administration	 (Figure	1A).	 Systolic	 and	di‐
astolic	blood	pressure	began	to	rise	significantly	at	day	10	and	day	
12,	respectively,	after	tamoxifen	administration	(Figure	1B)	and	uri‐
nary	protein/creatinine	ratio	augmented	significantly	at	day	12	after	
tamoxifen	administration	 (Figure	1C).	Blood	pressure	and	protein/
creatinine	 ratio	 continued	 to	 increase	until	 the	 end	of	 the	 experi‐
ment	at	28	days.	Oedema	was	regularly	encountered	in	all	Nphs2∆pod 
at	 3	weeks	 of	 the	 experiment.	 These	 results	 show	 in	 detail	 renal	
volume	handling	and	proteinuria	during	 the	development	of	NS	 in	
Nphs2∆pod	and	confirm	previous	published	data.3,18
3.2 | Analysis of renal function, morphology and 
expression of ENaC and its cleavage products in 
nephrotic syndrome during sodium retention
To	 analyse	 renal	 alterations	 in	 more	 detail,	 additional	 animal	 ex‐
periments	at	two	time‐points	after	tamoxifen	administration	were	
chosen:	 day	 5,	 during	 decreased	 sodium/creatinine	 ratio	 and	 day	
9,	when	blood	pressure	starts	to	rise.	Successful	podocin	deletion	
upon	tamoxifen	treatment	was	verified	and	confirmed	(Figure	2A).
Renal	 function	 analysis	 of	 mice	 at	 day	 5	 demonstrated	 reduced	
24	 hours	 sodium	excretion,	 urinary	Na/K	 ratio	 and	 fractional	 so‐
dium	excretion	in	Nphs2∆pod	compared	to	control	(Table	1).	Urinary	
albumin	excretion	started	to	rise	but	did	not	reach	statistical	signifi‐
cance.	At	day	9,	albuminuria	and	proteinuria	developed	significantly	
F I G U R E  1  Course	of	urinary	sodium/creatinine	ratio,	blood	
pressure	and	urinary	protein/creatinine	ratio	from	Con	and	
Nphs2∆pod.	A‐C,	Daily	urinary	sodium/creatinine	ratio	(A),	blood	
pressure	(B)	and	urinary	protein/creatinine	ratio	(C)	of	control	(Con)	
and	Nphs2∆pod	during	28	days.	Results	are	arithmetic	means	±	SEM	
of	n	=	5‐7	per	group;	*P	<	0.05.	tam	indicates	the	days	of	tamoxifen	
injection	to	induce	Nphs2	knockout
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F I G U R E  2  Assessment	of	podocin	deletion	and	glomerular	
morphology	during	sodium	retention.	Western	blots	of	podocin	
from	membrane	fractions	of	kidney	cortex	at	5	and	9	days	(A).	
Densitometric	evaluations	are	presented	in	the	graph	(right).	
Representative	images	of	PAS‐stained	sections	from	Con	and	
Nphs2∆pod	at	5	and	9	days	(B).	No	or	only	very	mild	glomerular	
and	no	tubule‐interstitial	alterations	were	found	at	5	and	9	days	
respectively.	Magnifications	scale	bar	=	20	µm.	Results	are	
arithmetic	means	±	SEM	of	n	=	5	per	group;	*P < 0.05
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(although	at	still	very	low	levels)	and	fractional	sodium	excretion	re‐
mained	low	in	Nphs2∆pod	compared	to	control.	Plasma	aldosterone	
and	vasopressin	 levels	remained	unchanged	at	time‐points	of	5,	9	
and	17	days	of	analysis.	Next,	morphological	alteration	of	glomeruli	
and	 tubulointerstitium	 of	 Nphs2∆pod	 were	 assessed	 by	 perform‐
ing	 a	 semi‐quantitative	 analysis	 of	 PAS‐stained	 paraffin	 sections	
(Figure	2B)	using	a	scoring	system	of	0‐4,	where	0	=	no	damage	and	
4	=	maximum	 score	of	 damage	encountered	 in	100%	of	 the	 area	
analysed.	At	day	5,	almost	all	glomeruli	appear	normal	and	a	very	
small	 fraction	 showed	 marginal	 glomerular	 alterations.	 At	 day	 9,	
mild	alteration	at	some	glomeruli	was	encountered	fitting	well	with	
the	significant	increase	in	albuminuria.	In	the	tubulointerstitium,	no	
tubular	alterations	were	 found	except	 for	one	 tubular	cast	at	day	
9.	These	results	demonstrate	that	glomeruli	and	tubulointerstitium	
are	 still	 intact	 at	 those	 time‐points,	which	 is	 congruent	with	nor‐
mal	plasma	creatinine	and	urea	values.	Because	ENaC	was	shown	
to	 play	 a	major	 role	 for	 sodium	 retention	 in	 other	 animal	models	
with	nephrotic	or	nephritic	syndrome,	cortical	and	medullary	ENaC	
expression	pattern	was	determined.	Comparing	Nphs2∆pod	to	con‐
trols,	 Western	 blots	 of	 membrane	 fractions	 isolated	 from	 renal	
cortices	and	medullae	at	5	days	(Figure	3A)	and	9	days	(Figure	3B)	
revealed	significantly	increased	expression	of	full‐length	α‐	and	γ‐
ENaC	subunit	and	cleaved	αENaC	fragments	at	30	kDa.	To	address	
the	question	whether	 the	occurrence	of	cleaved	αENaC	 is	due	to	
increased	overall	αENaC	levels	or	the	result	of	augmented	proteo‐
lytical	 cleavage,	we	 calculated	 the	 ratio	of	 cleaved	α‐	 and	γENaC	
in	relation	to	its	full‐length	subunit.	Increased	cleaved	αENaC	was	
observed	in	medulla	at	5,	9	and	17	days	(Table	2).	The	augmented	
expression	 level	of	full‐length	α‐	and	γENaC	was	not	due	to	tran‐
scriptional	alteration,	as	mRNA	of	α‐	and	γENaC	at	5	and	9	days	did	
not	change	(Figure	S1).	Because	apical	Na+	entry	is	tightly	coupled	
to	the	basolateral	Na+	extrusion,	we	determined	the	basolateral	α‐
subunit	Na+/K+‐ATPase	(αNKA)	expression	level	by	measuring	fluo‐
rescence	 intensity	 levels	 of	 cortical	 collecting	ducts	 identified	by	
aquaporin‐2	 expression	 (Figure	3C).	 Semi‐quantified	αNKA	abun‐
dance	from	micrographs	similar	to	(Figure	3C)	after	correction	for	
background	 signal,	 cell	 area,	 and	 normalization	 to	 control	 values	
revealed	significantly	increased	αNKA	fluorescence	at	5	and	9	days	
in	Nphs2∆pod	compared	to	the	controls.	This	demonstrates	that	aug‐
mented	transepithelial	sodium	reabsorption	may	involve	both	apical	
ENaC	and	basolateral	NKA.
3.3 | Assessment of Nphs2∆pod at day 17
Additionally,	we	performed	an	animal	experiment	using	control	and	
Nphs2∆pod	which	we	have	stopped	at	17	days	after	tamoxifen	ad‐
ministration	 for	 renal	 analysis	 at	 a	 later	 time‐point	when	NS	was	
fully	developed.	Plasma	analysis	of	Nphs2∆pod	compared	to	control	
revealed	reduced	albumin	and	protein	concentrations	and	increased	
creatinine	 levels	 (Table	 S2).	 Twenty‐four	 hours	 urine	 analysis	 of	
Nphs2∆pod	 compared	 to	 control	 revealed	 increased	 albumin	 and	
protein	excretion,	reduced	creatinine	clearance	and	increased	blood	
pressure.	Ascites	was	regularly	encountered	 in	Nphs2∆pod in com‐
parison	 to	 its	 control.	 Morphologically,	 glomeruli	 demonstrated	
pronounced	 podocyte	 hypertrophy,	 mesangial	 matrix	 deposition	
and	tubular	proteinous	casts	 (Figure	S2A).	Glomerular	 injury	scor‐
ing	showed	that	the	majority	of	glomeruli	 is	still	normal;	however,	
the	 amount	 of	 glomeruli	 appearing	 with	 severe	 alterations	 in‐
creased	 significantly	 (Figure	 S2B).	 Then,	 we	 performed	 Western	
blot	analysis	of	membrane	fractions	from	renal	cortex	and	medulla	
of	Nphs2∆pod	compared	 to	 control	 showing	 significantly	 increased	
ENaC	subunit	and	cleaved	α and γENaC	expression.	This	is	in	agree‐
ment	with	various	previously	published	results	on	volume	handling	
in	 NS.	 Additionally,	 we	 performed	 double	 labelling	 of	 NKA	 with	
aquaporin‐2	 to	 determine	 NKA	 fluorescence	 intensity	 levels	 in	
cortical	collecting	ducts,	which	were	significantly	increased	at	this	
time‐point	(Figure	2D	and	2).
TA B L E  1  Renal	functional	data	of	control	and	Nphs2∆pod	during	
sodium	retention	at	5	and	9	days	after	podocin	inactivation
Day 5 Day 9 n
WT	urine	Na+/crea 36.9	±	1.3 29.7	±	2.3 5‐6
KO	urine	Na+/crea 27.7	±	4.6*  32.0	±	2.1 6‐7
WT	urine	Na+/K+ 0.81	±	0.07 0.68	±	0.09 5‐6
KO	urine	Na+/K+ 0.58	±	0.08*  0.56	±	0.07 6‐7
WT	urine	albumin	
(mg/L)
0.83	±	0.3 1.17	±	0.5 5‐6
KO	urine	albumin	
(mg/L)
5.12	±	2.3 118.1	±	5.4**  6‐7
WT	urine	protein	(g/L) 1.36	±	0.06 0.42	±	0.8 5‐6
KO	urine	protein	(g/L) 2.11	±	1.12 4.88	±	1.7**  6‐7
WT	Fractional	Na+ 
excretion,	FENA	(%)
0.37	±	0.03 0.34	±	0.03 5‐6
KO	Fractional	Na+ 
excretion,	FENA	(%)
0.27	±	0.03*  0.22	±	0.02*  6‐7
Results	are	arithmetic	means	±	SEM	of	n	=	5‐7	per	group.
*P	<	0.05,	
**P < 0.01. 
F I G U R E  3  Assessment	of	ENaC	subunit	and	collecting	duct	Na+/K+‐ATPase	expression	levels	during	sodium	retention.	Western	blots	of	
α‐,	β‐	and	γENaC	from	membrane	fractions	of	kidney	cortex	and	medulla	at	5	(A)	and	9	days	(B).	Specific	bands	are	marked	by	green	brackets.	
Densitometric	evaluations	are	presented	in	the	respective	graphs	below.	Ponceau	red	staining	and	β‐actin	served	as	loading	control.	Results	
are	arithmetic	means	±	SEM	of	n	=	5‐7	per	group;	*P	<	0.05,	**P	<	0.005.	Immunohistochemical	double	labelling	of	Na+/K+‐ATPase	(red)	and	
aquaporin‐2	(green)	for	the	identification	of	collecting	ducts	(C).	Collecting	ducts	are	marked	by	an	asterisk.	Significantly	increased	collecting	
duct	Na+/K+‐ATPase	expression	is	encountered	in	Nphs2∆pod	at	5	and	9	days	compared	to	control	(Con)	as	depicted	in	the	graph	aside.	
Magnifications	scale	bar	=	20	µm.	Results	are	arithmetic	means	±	SEM	of	n	=	5	per	group;	*P < 0.05
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3.4 | Effects of amiloride in the nephrotic syndrome 
development
To	see	and	prove	whether	ENaC	is	activated	and	responsible	for	the	
reduced	 urinary	 sodium/creatinine	 ratio	 early	 in	 the	 NS	 develop‐
ment,	an	additional	animal	experiment	was	conducted	with	amiloride	
(Figure	4).	As	shown	before,	compared	to	their	controls	Nphs2∆pod/
vehicle	 demonstrated	 significantly	 reduced	 urinary	 sodium/creati‐
nine	ratio	between	day	4	and	day	7.	Administration	of	amiloride	to	
control	 increased	 urinary	 sodium/creatinine	 ratio	 at	 baseline	 and	
strongly	augmented	in	Nphs2∆pod/amiloride	between	day	5	and	day	
8,	proving	increased	ENaC	activity	early	in	NS	development.
3.5 | Urinary protease excretion
Because	of	the	early	αENaC	processing	already	at	5	days	after	FSGS	
induction,	 we	 analysed	 the	 urine	 of	 Nphs2∆pod	 and	 their	 controls	
from	 day	 2	 until	 day	 16.	 In	 controls,	 a	 zymogram‐positive	 band	
was	observed	at	above	260	kDa,	which	also	occurred	 in	 the	urine	
of	Nphs2∆pod	with	 a	 constant	 intensity	 over	 the	 time	 (Figure	 5A).	
Surprisingly,	 already	 at	 day	2	 proteolytic	 activity	was	 observed	 in	
the	 urine	 of	 Nphs2∆pod.	 With	 time,	 intensity	 of	 zymogram‐posi‐
tive	bands	increased	as	well	as	the	number	of	proteases	running	at	
different	molecular	weight.	At	2	days,	a	band	at	140‐160	kDa	was	
found,	at	day	6	an	additional	band	at	100	kDa	was	observed,	at	day	
8	a	band	at	70	kDa	was	observed,	and	at	days	10	and	12	bands	at	
85	kDa	and	60	kDa	was	found	respectively.	Additionally,	a	band	at	
25	kDa	from	day	2	to	6	was	observed.	Then,	we	aimed	to	identify	
the	protease	responsible	for	the	proteolysis	of	ENaC.	Therefore,	the	
urine	of	Nphs2∆pod	from	day	2	until	day	9	was	collected,	HPLC‐puri‐
fied	and	the	resulting	80	fraction	tested	on	their	proteolytic	activ‐
ity	by	gel	zymography.	Eleven	 fractions	were	 found	to	be	positive	
and	 neighbouring	 fractions	with	 the	 same	molecular	weight	were	
pooled.	Fractions	8‐9,	10‐11,	12‐13,	14‐15,	16	and	17‐18	were	tested	
for	 their	 ability	 to	 augment	 ENaC	 activity.	 Fractions	 8‐9,	 10‐11,	
12‐13	and	16	significantly	 increased	amiloride‐sensitive	equivalent	
transepithelial	currents	in	mpkCCDcl14	cells	(data	not	shown).	All	six	
protease‐positive	HPLC	fractions	were	analysed	by	 liquid	chroma‐
tography	 (LC)‐tandem	mass	 spectrometry	 (MS/MS)	 and	 identified	
proteases	are	summarized	in	Table	3.	The	identified	proteases	were	
typically	 present	 in	multiple	HPLC	 fractions;	 hence	 they	 are	 sum‐
marized	as	a	joint	list.
3.6 | ENaC subunit processing and activation by 
lysosomal enzymes
Based	on	our	results,	we	were	focusing	on	αENaC	cleaving	enzymes	
and	identified	cathepsin	B	(see	Table	3),	which	was	shown	previously	
TA B L E  2  Ratio	of	cleaved	α‐or	γENaC	in	relation	to	its	full‐
length	subunit.	Calculated	ratio	of	the	abundance	of	cleaved	
ENaC	in	relation	to	its	full‐length	subunit	of	cortical	and	medullary	
membrane	fractions	at	5,	9	and	17	days.	Increased	ratio	of	cleaved	
αENaC	is	found	in	the	medulla	at	all	time‐points	analysed
Cortex Medulla
5	days
αENaC	cl/αENaC	fl 0.71 1.23
γENaC	cl/γENaC	fl 0.85 0.47
9	days
αENaC	cl/αENaC	fl 0.84 1.39
γENaC	cl/γENaC	fl 0.73 0.44
17	days
αENaC	cl/αENaC	fl 0.94 1.98
γENaC	cl/γENaC	fl 1.05 1.06 F I G U R E  4  Course	of	urinary	sodium/creatinine	ratio	from	
Con	and	Nphs2∆pod	treated	with	amiloride.	Daily	urinary	sodium/
creatinine	ratio	of	control	(Con)	and	Nphs2∆pod	treated	with	vehicle	
or	amiloride	(10	µg/g	ip)	during	14	days.	Urine	was	collected	
4	hours	after	injection	of	vehicle	or	amiloride.	tam	indicates	the	
days	of	tamoxifen	injection	to	induce	Nphs2	knockout.	Results	are	
arithmetic	means	±	SEM	of	n	=	5‐7	per	group;	*P	<	0.05	Nphs2∆pod/
vehicle	versus	control/vehicle;	#P	<	0.05	Nphs2∆pod/amiloride 
versus	control/amiloride;	and	§P	<	0.05	control/amiloride	versus	
control/vehicle
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F I G U R E  5  Presence	of	urinary	protease	activity,	in	vitro	protease	assays	and	proteolytic	ENaC	activation.	Representative	zymograms	
of	urine	loaded	in	normalization	to	urinary	creatinine	from	control	(Con)	and	Nphs2Δpod	obtained	from	day	2	to	day	16	(A).	Arrows	mark	
protease‐positive	bands.	B,	Western	blots	of	protease	assays	using	αENaC‐GST,	βENaC‐GST	or	γENaC‐GST	incubated	either	with	cathepsin	
B	(CatB),	cathepsin	D	(CatD),	cathepsin	E	(CatE)	or	legumain	(LGMN).	In	the	case	of	β‐	and	γENaC	trypsin	(tryp)	was	used	as	a	positive	
control.	In	the	case	of	γENaC‐GST,	to	observe	the	trypsin	cleaved	band,	Western	blot	exposure	time	was	increased	(extract	on	the	right).	C,	
Equivalent	short	circuit	current	of	mpkCCDcl14	monolayers	incubated	either	with	trypsin,	which	served	as	positive	control,	or	CatB,	CatD,	
CatE	or	legumain	over	a	time	period	of	240	min.	Results	are	means	±	SEM	of	n	=	3	per	group	per	experiment.	Experiments	were	repeated	
four	times,	*P < 0.05
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to	activate	ENaC	currents	by	proteolytical	processing	of	αENaC.19 
We	have	been	suggested	that	there	maybe	also	other	lysosomal	en‐
zymes,	as	 found	and	highlighted	 in	Table	3,	may	be	able	 to	cleave	
αENaC.	Performing	 in	 vitro	 protease	 assays	 using	αENaC‐GST	 fu‐
sion	proteins,	we	 found	cathepsin	B	cleaved	αENaC	at	 the	known	
‘furin’	cleavage	site	with	a	resulting	product	at	30	kDa	(Figure	5B).	
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Cathepsin	D	cleaved	αENaC	at	an	unknown	site	with	resulting	prod‐
ucts	 at	 approx.	 38	 and	 50	 kDa.	 Cathepsin	 E	 and	 legumain	 were	
unable	 to	 process	 αENaC.	 Incubating	 γENaC‐GST	 fusion	 protein	
with	 lysosomal	 enzymes	 showed	 that	 cathepsin	D	 faintly	 cleaved	
γENaC	at	 the	appropriate	 site	with	a	 resulting	product	 at	70	kDa,	
see	positive	control	using	trypsin.	Legumain	processed	γENaC	at	ap‐
prox.	72	kDa.	Cathepsins	B	and	E	were	unable	 to	process	γENaC.	
Incubating	 βENaC‐GST	 fusion	 proteins	 with	 lysosomal	 enzymes	
did	not	result	in	proteolytical	processing,	demonstrating	the	speci‐
ficity	of	lysosomal	enzymes	for	a	specific	subunit.	Next,	we	tested	
the	 ability	 of	 the	 lysosomal	 enzymes	 to	 augment	 ENaC	 activity.	
Incubating	mpkCCDcl14	 cell	 monolayers	with	 cathepsin	 B	 resulted	
in	a	significant	augmentation	of	equivalent	transepithelial	currents	
within	30	minutes	(Figure	5C).	Cathepsin	D	and	legumain	increased	
equivalent	 transepithelial	 currents	 after	 2	 hours.	 For	 comparison,	
trypsin	 increased	equivalent	 transepithelial	current	within	15	min‐
utes.	Cathepsin	E	did	not	alter	the	equivalent	transepithelial	current.
3.7 | Increased cathepsin B expression level in 
Nphs2∆pod
Next,	 the	 proteases	 furin,	 cathepsin	 B	 and	D	were	 analysed	 on	
their	 expression	 level.	Western	 blot	 analysis	 of	 cathepsin	 B	 re‐
vealed	significantly	augmented	expression	in	Nphs2∆pod	compared	
to	their	controls	at	5	and	at	9	days	after	tamoxifen	administration	
(Figure	 6A	 and	 6	 respectively).	 Furin	 and	 cathepsin	D	 remained	
unaltered	 (results	 for	 cathepsin	 D	 are	 not	 shown).	 For	 cellular	
analysis,	 immunohistochemical	 staining	 of	 cathepsin	 B	 was	 per‐
formed.	Triple	labelling	of	cathepsin	B,	lysosomes	and	podocytes	
after	5	days	revealed	 increased	vesicular	cathepsin	B	expression	
in	podocytes	and	after	9	days,	it	overall	increased	vesicular	cath‐
epsin	B	staining	within	podocytes	and	glomerulus	(Figure	6C	and	
6’).	In	the	proximal	tubule,	cathepsin	B	was	observed	in	lysosomes.	
Surprisingly,	a	strong	increase	in	cathepsin	B	in	intercalated	cells	
was	detected	at	5	and	at	9	days	(Figure	6D	and	6).	Additionally,	we	
followed	the	hypothesis	 that	 increased	proximal	 tubular	albumin	
uptake	may	activate	endocytosis	and	that	lysosomal	enzymes	may	
appear	in	the	urine	upon	lysosomal	spill	over.	Therefore,	we	deter‐
mined	endocytosed	albumin	in	proximal	tubular	profiles,	identified	
by	double	labelling	with	megalin	(Figure	S3A).	At	5	days,	no	differ‐
ence	 in	 albumin	 fluorescence	was	 observed	 between	Nphs2∆pod 
and	 control.	 At	 9	 days	 and	more	 pronounced	 at	 17	 days,	 endo‐
cytosed	albumin	 increased	significantly.	As	sodium	retention	oc‐
curs	 between	 days	 4‐7	 it	 seems	 unlikely,	 that	 increased	 urinary	
cathepsin	B	stems	from	the	proximal	tubular	 lysosome	spill	over.	
Additionally,	we	performed	coomassie	staining	of	SDS‐PAGE	and	
Western	 blots	 from	 daily	 spot	 urine	 loaded	 after	 creatinine	 ad‐
justment	 (Figure	S3B).	Albuminuria	was	 starting	at	days	4‐6	and	
unselective	 gross	 proteinuria	 on	 days	 13‐14.	 Western	 blots	 of	
cathepsin	 B	 showed	 increased	 active	 sc‐cathepsin	 B	 expression	
early	 between	 day	 4	 and	 7,	 whereas	 plasminogen	 and	 plasmin	
started	 to	 increase	at	days	13‐14.	We	also	 tested	whether	albu‐
min	may	activate	cathepsin	B	expression	in	cortical	collecting	duct	
cells	and	 incubated	mpkCCDcl14	 cells	with	albumin	at	concentra‐
tions	 ranging	 from	0	 to	20	mg/mL	 for	6	hours	and	at	10	mg/mL	
for	0,	3,	6	and	24	hours;	however,	no	significant	changes	were	ob‐
served	(data	are	not	shown).
3.8 | Impacts of cathepsin B inhibitor CA‐074Me in 
Nphs2∆pod
To	 analyse	whether	 cathepsin	 B	may	 impact	 the	 disease	 progres‐
sion	in	Nphs2∆pod,	an	additional	animal	experiment	was	performed	
with	 control	 and	 Nphs2∆pod	 receiving	 either	 CA‐074Me	 (a	 mem‐
brane‐permeable	cathepsin	B	inhibitor)	or	vehicle	for	14	days	start‐
ing	 on	 the	 day	 after	 the	 first	 tamoxifen	 injection.	 As	 expected	 at	
day	 9,	 Nphs2∆pod	 receiving	 vehicle	 developed	 significantly	 higher	
blood	pressure,	which	remained	high	until	the	end	of	the	experiment	
TA B L E  3  Proteases	identified	from	HPLC‐purified	urine	of	
Nphs2∆pod	from	day	2	until	day	9	after	podocin	inactivation.	Protein	
name,	gene	name	and	protein	ID	of	the	identified	proteases	are	
listed.	Lysosomal	proteases	are	marked	in	bold	and	known	γENaC	
cleaving	proteases	are	marked	in	cursive
Protein name Gene name Protein ID
Hepatocyte	growth	factor	
activator
Hgfac Q9R098
Napsin‐A Napsa O09043
Legumain Lgmn O89017
Complement	factor	D Cfd P03953
Complement	factor	B Cfb P04186
Lactotransferrin Ltf P08071
Angiotensin‐converting	
enzyme
Ace P09470
Cathepsin B Ctsb P10605
Kallikrein‐1 Klk1 P15947
Glutamyl	aminopeptidase Enpep P16406
Lysosomal protective protein Ctsa P16675
Cathepsin D Ctsd F6Y6L6
Prothrombin F2 H7BX99
Plasminogen Plg P20918
Meprin	A	subunit	alpha Mep1a P28825
Cathepsin E Ctse D3Z6T3
Aminopeptidase	N Anpep P97449
Complement	factor	I Cfi Q61129
Haptoglobin Hp Q61646
Meprin	A	subunit	beta Mep1b Q61847
Lysosomal	Pro‐X	
carboxypeptidase
Prcp Q7TMR0
Serotransferrin Tf Q921I1
Dipeptidyl	peptidase	2 Dpp7 Q9ET22
Acid	ceramidase Asah1 Q9WV54
Mast	cell	protease‐11 Prss34 Q80UR4
Prostasin Prss8 Q99L44
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at	 14	 days	 (Figure	 S4).	 Blood	 pressure	 of	 Nphs2∆pod	 receiving	
CA‐074Me,	however,	remained	at	control	levels.
4  | DISCUSSION
Proteinuria,	volume	retention	and	subsequent	hypertension	and/
or	oedema	are	hallmarks	of	the	NS	and	possible	mechanisms	have	
been	identified	previously.	The	murine	model	of	targeted	podocin	
gene	inactivation	was	shown	to	develop	the	entire	characteristics	
of	FSGS	with	NS	until	the	fourth	week	after	induction3	allowing	us	
to	carefully	examine	 renal	 function	 in	a	 time‐dependent	manner	
over	a	 longer	time	period	then	in	animal	models	of	PAN‐induced	
nephrosis	or	doxorubicin‐induced	NS.10,14,16,17	We	have	observed	
sodium	retention,	hypertension	and	gross/unselective	proteinuria	
to	occur	in	a	chronologic	successive	order.	Focusing	on	the	time‐
point	 of	 sodium	 retention	between	day	4	 and	7	 and	 start	 of	 in‐
creased	 blood	 pressure	 at	 day	 9	 after	 tamoxifen	 administration,	
F I G U R E  6  Furin	and	cathepsin	B	
expression	during	sodium	retention.	
Western	blots	and	densitometrical	
evaluation	of	furin	and	cathepsin	B	
occurring	as	proenzyme	(proCatB),	as	
active	enzyme	single	chain	(SC‐CatB)	
or	heavy	chain	(HC‐CatB)	from	renal	
membrane	fractions	of	control	(Con)	and	
Nphs2∆pod	at	5	days	(A)	and	9	days	(B).	
Results	are	arithmetic	means	±	SEM	of	
n	=	5	per	group;	*P	<	0.05.	C	and	C’,	Merge	
images	of	immunohistochemical	triple	
labelling	using	cathepsin	B	(red),	lysosomal	
marker	Lamp‐1	(blue)	and	podocyte	
maker	nephrin	(green),	in	control	(Con)	
and	Nphs2∆pod	at	5	days	and	9	days.	
Magnification	scale	bar	=	20	µm.	C’,	
Magnification	of	insert.	Arrowheads	mark	
strong	CatB	expression	in	podocytes.	
Magnification	scale	bar	=	10µm.	D	and	E,	
Immunohistochemical	double	labelling	of	
cathepsin	B	(CatB,	red)	and	intercalated	
cell	marker	β1‐subunit	of	the	V‐ATPase	
(green)	in	control	and	Nphs2∆pod	at	5	days	
(C)	and	9	days	(D).	Arrowheads	mark	
strong	CatB	expression	in	intercalated	
cells.	Magnifications	scale	bar	=	50	µm
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analysis	 of	 ENaC	 expression	 pattern	 was	 surprising.	 Increased	
occurrence	 of	 cleaved	αENaC	 fragments	 and	 abundance	 of	 full‐
length	ENaC	subunits	without	changes	 in	aldosterone	and	vaso‐
pressin	levels	were	observed.	An	increased	ENaC	abundance	was	
found	 previously	 in	 many	 other	 proteinuric	 animal	 models.6‐9 
Augmented	 ENaC	 function,	 however,	 seems	 to	 be	 unrelated	 to	
hormonal	 stimulation,	 as	 various	 hormonal	 blockades	 did	 not	
change	 the	 clinical	 outcome.7,10	 Transcriptional	 regulation	 can	
also	be	excluded	as	ENaC	mRNA	expressions	 levels	neither	vary	
at	5	nor	at	9	days,	similarly	as	previously	reported.20	In	Nphs2∆pod,	
the	augmented	ENaC	expression	levels	and	or	αENaC	cleavage	at	
5	and	9	days	 is	of	 functional	 relevance	because	NKA	expression	
levels	from	the	cortical	collecting	duct	are	consistently	increased	
compared	 to	 control	 and	 other	 nephron	 segments	 in	 the	 same	
section.	 Supporting	 evidence	 for	 early	 increased	 ENaC	 activity	
was	gained	from	daily	administration	of	amiloride	to	control	and	
Nphs2∆pod.	Highest	plasma	values	 for	 amiloride	occur	3‐4	hours	
after	amiloride	administration,	the	time‐point	where	sodium	was	
determined	 from	spot	urine.	From	our	experiment,	we	observed	
that	between	day	5	and	9	before	sodium/creatinine	ratio	increased	
in	 control/amiloride	 and	 augmented	 strongly	 in	 Nphs2∆pod/ami‐
loride	 suggesting	 that	 using	 this	 application	 procedure	 sodium/
creatinine	ratio	mirrors	ENaC	channel	activity.	These	results	sup‐
port	the	overfill	hypothesis	where	sodium	retention	 is	related	to	
an	intrinsic	renal	defect	in	sodium	handling.
With	disease	progression,	proteinuria	establishes,	plasma	albu‐
min	values	decrease	and	oedema	can	be	 regularly	encountered	at	
17	days	of	analysis.	Those	later	changes	support	rather	the	under	fill	
hypothesis	where	decreased	plasma	oncotic	pressure	by	hypoalbu‐
minemia	and	 fluid	shifts	 from	 intravascular	 to	 the	 interstitial	com‐
partment	can	be	found.
The	 appearance	 of	αENaC	 fragments	 at	 5	 days	 suggests	 the	
existence	of	 local	 proteases;	 therefore,	 the	urine	was	 tested	 for	
proteolytic	 activity.	 Already	 at	 the	 second	 day	 of	 animal	 exper‐
iment,	 elevated	 levels	of	 proteases	 can	be	 found	 in	 the	urine	of	
Nphs2∆pod	which	constantly	 increase	with	the	time.	From	HPLC‐
purified	urine	of	Nphs2∆pod,	we	identified	known	γENaC	cleaving	
proteases,	 such	 as	 prostasin20,21	 kallikrein‐112,22,23	 plasminogen	
and	 prothrombin.12	 Additionally,	 several	 lysosomal	 proteases,	
among	them	cathepsin	B,	‐D,	‐E	and	legumain	were	encountered.	
Focusing	on	putative	αENaC	cleaving	enzymes,	we	could	confirm	
the	results	of	A.	Alli	et	al13	showing	proteolytic	αENaC	processing	
by	 cathepsin	B	 resulting	 in	 increased	 relative	 currents	 in	mpkC‐
CDcl14	 cells.	Among	other	 lysosomal	 proteases	 only	 cathepsin	D	
cleaved αENaC;	however,	at	a	yet	unknown	site	leading	to	50	and	
40	kDa	fragments.	Whether	cathepsin	D	cleavage	is	of	functional	
relevance	needs	to	be	identified	in	future.	Additionally,	we	tested	
whether	the	 identified	 lysosomal	proteases	cleave	αENaC.	Using	
trypsin	as	positive	control,	we	observed	a	very	mild	processing	by	
cathepsin	D	 and	 legumain	 by	 in	 vitro	 protease	 assays.	Although	
Tan	et	al24	reported	that	cathepsin	B	cleaves	αENaC	and	γENaC,	
we	did	not	observe	γENaC	processing	which	may	be	due	to	differ‐
ences	 in	techniques	and	models	used.	The	very	faint	cleavage	of	
γENaC	by	cathepsin	D	at	70	kDa	and	 legumain	at	72	kDa	corre‐
sponds	to	the	increase	in	relative	currents	in	mpkCCDcl14	cells	at	
2	hours.	A	more	detailed	analysis	for	further	exploration	needs	to	
be	performed	in	future.
In	Nphs2∆pod	during	the	time	of	early	sodium	retention	between	
day	5	and	9,	overall	glomerular	morphology	remains	largely	intact,	
the	 glomerular	 filter	 however	 is	 altered	 and	 shows	 albuminuria/
selective	 proteinuria.	 Therefore,	 plasma	 proteases	 as	 shown	 for	
plasminogen	are	still	unable	to	pass	and	do	not	account	for	the	so‐
dium	retention	during	this	period	assuming	that	urinary	proteases	
identified	might	stem	from	the	kidney	 itself.	Lysosomal	cathepsin	
B	activation	and	proximal	tubular	spill	over	into	the	primary	ultra‐
filtrate	was	postulated	to	account	for	increased	urinary	cathepsin	
B	 activity	 in	 proteinuric	 diseases.25	 However,	 analysis	 of	 endog‐
enous	expression	of	 taken‐up	albumin	and	β2‐microglobulin,	 as	a	
low‐molecular	weight	protein,	did	not	change	at	five	days	and	was	
slightly	increased	at	9	days	(data	not	shown);indicating	that	it	can‐
not	account	 for	 increased	cathepsin	B	activity	at	 least	 at	5	days.	
Furthermore,	we	tested	whether	albumin	may	augment	cathepsin	B	
expression	levels;	however,	no	obvious	alterations	were	observed.	
Immunohistochemical	 localization	of	 cathepsin	B	 revealed	 strong	
expression	in	proximal	tubular	profiles	and	to	lesser	extent	in	the	
glomerulus,	distal	tubule	and	collecting	duct	system.	Because	of	the	
high	proximal	 tubular	 levels	of	 endogenous	 cysteine	protease	 in‐
hibitors,	cystatin	C,26	proximal	tubular‐derived	cathepsin	B	may	not	
contribute	much	to	the	increased	renal	expression	levels	observed	
in	Western	blots.	In	Nphs2∆pod	at	5	and	9	days,	increased	cathepsin	
B	 expression	was	 found	 in	 glomeruli	 and	more	 strongly	 in	 inter‐
calated	cells;	therefore,	we	assume	that	either	glomerulus‐derived	
cathepsin	B	via	ultrafiltrate	or	intercalated	cell‐derived	cathepsin	B	
paracrine	reach	the	principal	cells	for	αENaC	cleavage	and	there‐
fore	ENaC	channel	 activation.	The	 important	 role	of	 cathepsin	B	
in	 renal	 disease	 progression	was	 demonstrated	 recently	 showing	
that	cathepsin	B	knockout	mice	were	more	resistant	and	recovered	
faster	after	glomerular	damage	upon	podocyte	 injury	 induced	by	
nephrotoxic	serum.27
In	summary,	using	the	Nphs2∆pod	mice,	we	were	able	to	identify	
the	 chronology	 of	 the	 development	 of	 hallmarks	 of	 the	NS.	 Early	
after	genetic	Nphs2	 deletion,	 sodium	 retention	occurred,	 followed	
by	hypertension	and	gross	proteinuria.	This	early	sodium	retention	is	
based	on	augmented	ENaC	activity	through	proteolytical	processing	
of	αENaC.	Cathepsin	B	was	 identified	 as	αENaC	 cleaving	 enzyme	
where	its	blockade	prevented	hypertension.
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